- Home
- UPST vs RNA Comparison
UPST vs RNA Comparison
Compare UPST & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- RNA
- Stock Information
- Founded
- UPST 2012
- RNA 2012
- Country
- UPST United States
- RNA United States
- Employees
- UPST N/A
- RNA N/A
- Industry
- UPST Finance: Consumer Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- RNA Health Care
- Exchange
- UPST Nasdaq
- RNA Nasdaq
- Market Cap
- UPST 3.2B
- RNA 4.7B
- IPO Year
- UPST 2020
- RNA 2020
- Fundamental
- Price
- UPST $34.40
- RNA $40.46
- Analyst Decision
- UPST Hold
- RNA Strong Buy
- Analyst Count
- UPST 12
- RNA 7
- Target Price
- UPST $26.75
- RNA $55.86
- AVG Volume (30 Days)
- UPST 7.4M
- RNA 1.4M
- Earning Date
- UPST 08-06-2024
- RNA 08-09-2024
- Dividend Yield
- UPST N/A
- RNA N/A
- EPS Growth
- UPST N/A
- RNA N/A
- EPS
- UPST N/A
- RNA N/A
- Revenue
- UPST $575,957,000.00
- RNA $10,599,000.00
- Revenue This Year
- UPST $5.62
- RNA $23.84
- Revenue Next Year
- UPST $27.82
- RNA N/A
- P/E Ratio
- UPST N/A
- RNA N/A
- Revenue Growth
- UPST 2.52
- RNA 8.15
- 52 Week Low
- UPST $19.84
- RNA $4.83
- 52 Week High
- UPST $49.62
- RNA $48.80
- Technical
- Relative Strength Index (RSI)
- UPST 45.64
- RNA 41.80
- Support Level
- UPST $41.05
- RNA $39.62
- Resistance Level
- UPST $45.71
- RNA $44.61
- Average True Range (ATR)
- UPST 2.92
- RNA 1.99
- MACD
- UPST -1.15
- RNA -0.51
- Stochastic Oscillator
- UPST 5.28
- RNA 16.68
About UPST Upstart Holdings Inc. Common stock
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.